|
Jun 5
|
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”
|
|
Jun 3
|
Arrowhead commences dosing in Phase I/IIa obesity treatment trial
|
|
Jun 2
|
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
|
|
May 29
|
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
|
|
May 12
|
Arrowhead Research: Fiscal Q2 Earnings Snapshot
|
|
May 12
|
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
|
|
May 7
|
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
|
|
May 7
|
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
|
|
Apr 15
|
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
|
|
Mar 10
|
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
|
|
Mar 10
|
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
|
|
Feb 20
|
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now
|
|
Jan 17
|
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
|
|
Dec 7
|
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week
|
|
Dec 4
|
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment
|
|
Dec 3
|
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
|
|
Dec 3
|
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
|
|
Dec 2
|
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
|
|
Sep 24
|
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
|
|
Sep 23
|
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners
|